• AstraZeneca receives DCG(I) nod for Durvalumab in India financialexpress
    June 29, 2018
    AstraZeneca Pharma India Limited (AZPIL) has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General India, DCG(I). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India,
PharmaSources Customer Service